As associate director in Innovate Carolina’s Office of Technology Commercialization, Dean Stell helps Carolina researchers get their discoveries to market – creating economic and human good for the University, state and world.
Carolina-affiliated startup Pulvinar Neuro’s novel treatment for mental illness – a technology that uses closed-loop, non-invasive stimulation of brain waves – offers hope to a rising tide of patients and recently led to the company’s acquisition by medical device leader Electromedical Products International.
Between the pandemic, international unrest, natural disasters and the mounting underlying pressures of daily life, the challenges of mental health and mental illness are surfacing more than ever. According to the National Alliance on Mental Illness, more than one in five adults in the U.S. experience mental illness, and more than one in 15 experienced both
Share
Patients with genetic lysosomal storage diseases – particularly children – are living longer because of better treatments. But with promising advances and longer lives comes complications, the loss of eyesight as these rare diseases take their toll over time.
Lysosomal storage diseases are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body’s cells as a result of enzyme deficiencies, according to the National Organization for Rare Disorders. With these diseases, patients are missing the mucopolysaccharidosis type 1 (MPS1) gene. Current therapies that allow patients to live longer don’t address corneal clouding caused by these diseases. However, one Carolina-affiliated startup, RainBio, is developing a novel gene therapy for MPSI corneal blindness, giving patients a chance not only for longer lives but better ones.
Patients with genetic lysosomal storage diseases – particularly children – are living longer because of better treatments. But with promising advances and longer lives comes complications, the loss of eyesight as these rare diseases take their toll over time.
Lysosomal storage diseases are inherited metabolic diseases that are characterized by an abnormal build-up of various toxic materials in the body’s cells as a result of enzyme deficiencies, according to the National Organization for Rare Disorders. With these diseases, patients are missing the mucopolysaccharidosis type 1 (MPS1) gene. Current therapies that allow patients to live longer don’t address corneal clouding caused by these diseases. However, one Carolina-affiliated startup, RainBio, is developing a novel gene therapy for MPSI corneal blindness, giving patients a chance not only for longer lives but better ones.